Register to receive a free Cardiac Rhythm Management Market Analysis, Size and Trends Report synopsis and brochure.
Baylis Medical, a developer of innovative cardiological devices and therapies, recently announced the introduction of its EPstar Fixed Electrophysiology Catheters into the North American market. The newly introduced family of products includes the 2F catheter and the 6F guiding catheter. These are used in conjunction, in order to allow for deeper coronary sinus (CS) mapping. Baylis Medical’s EP catheters will allow physicians to map areas of the heart that were not accessible before. Furthermore, the improved mapping will aid in diagnosing diseases such as idiopathic ventricular tachycardias, complex atrial tachycardias and left Wolff-Parkinson-White Syndrome.
The 2F catheter can be delivered through any venous access point, allowing physicians to create a tailored approach for the patient’s anatomy. The 6F guiding catheter includes a lumen, which will help visualize the coronary sinus anatomy. Japan Lifeline (JLL), a cardiovascular device developer and manufacturer, has partnered with Baylis Medical to launch the EPstar catheters.
Expert insight from iData Research has determined that there has been an increase in the proportion of diagnostic EP catheters used that incorporate localization (mapping) capabilities. Due to the introduction of more advanced steerable and mapping catheters, the ASP of mapping EP catheters has increased to surpass that of their non-mapping counterparts. In addition, there has been an increased number of catheter-based cardiac ablation procedures performed. As it offers the ability to map the coronary sinus deeper than other devices in the North American market, the electrophysiology catheter market segment can expect positive growth.
Miguel Valderrabano, M.D., director of cardiac electrophysiology at Houston Methodist Hospital, emphasized that “mapping of the coronary sinus is essential to determine an accurate diagnosis for several cardiac conditions. However, it becomes a challenge as you reach further into coronary sinus small branches, which cannot be reached with conventional catheters.” He added that “the availability of a 2F catheter allows us to reach into those smaller areas of the CS and VOM, as well as the anterior interventricular vein at its small branches, to achieve an accurate diagnosis.”
Dr. Valderrabano is the first North American physician to use the EPstar 2F catheter in a clinical procedure.
For Further Information
To get in an in-depth market overview, as well as insight through primary research and procedural volumes from 10 countries, please read iData Research’s’ 1264 page Cardiac Rhythm Management Market Analysis, Size and Trends Report.